墨蝶呤还原酶抑制减轻小鼠炎性关节痛并提升尿墨蝶呤水平
该研究在胶原抗体诱导性关节炎(CAIA)小鼠模型中评估SPR抑制的抗炎与镇痛作用,并分析小鼠及健康志愿者尿墨蝶呤水平作为靶点结合生物标志物的可行性。结果显示SPR抑制减轻热痛觉过敏和晚期机械性异常性疼痛而不影响炎症体征,尿墨蝶呤升高预测靶点结合的敏感度和特异度较高。
要点
- SPR抑制可减轻CAIA小鼠的热痛觉过敏和晚期机械性异常性疼痛,但不改变炎症体征。
- 尿墨蝶呤水平升高可预测小鼠和健康人的SPR抑制/靶点结合,敏感度和特异度较高。
- 尿四氢生物蝶呤在CAIA小鼠炎症期较对照升高2倍且被SPR抑制显著降低。
核心结论
- SPR抑制可减轻关节炎症相关疼痛,提示其作为炎性关节痛镇痛策略的潜力。
- SPR抑制升高尿墨蝶呤水平,提示该指标可作为SPR抑制剂靶点结合的无创生物标志物。
研究设计与样本
- 研究采用胶原抗体诱导性关节炎(CAIA)小鼠模型诱导关节炎症。
- 在小鼠中检测SPR药理抑制对热、冷、机械诱发痛敏阈值及炎症体征的影响。
- 小鼠与健康人类志愿者接受SPR抑制剂处理,用高效液相色谱分析尿墨蝶呤水平变化。
主要发现
- CAIA小鼠分两阶段:急性炎症早期有 joint inflammation 及热、机械、冷诱导痛敏。
- 炎症后期无关节炎症,但存在热和机械诱导痛敏,无冷痛敏。
- SPR抑制显著减轻CAIA小鼠两阶段的热痛觉过敏及后期的机械性异常性疼痛。
- SPR抑制不影响炎症体征。
- CAIA小鼠炎症期尿四氢生物蝶呤较对照升高2倍(P < 0.05),SPR抑制后显著降低(P < 0.05 对比溶媒处理小鼠)。
关键数值与推荐
- 尿墨蝶呤升高预测SPR抑制/靶点结合的敏感度为70-85%,特异度为82-88%。
- CAIA小鼠炎症期尿四氢生物蝶呤较对照升高2倍(P < 0.05)。
- SPR抑制后尿四氢生物蝶呤较溶媒处理小鼠显著降低(P < 0.05)。
临床怎么用
- SPR抑制可能作为炎性关节痛的镇痛策略,但本研究为小鼠模型,尚需临床验证。
- 尿墨蝶呤或可作为SPR抑制剂(如柳氮磺吡啶)靶点结合的无创监测指标。
- SPR抑制不影响炎症体征,临床镇痛应用需与抗炎治疗区分定位。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the antiinflammatory and analgesic effects of sepiapterin reductase (SPR) inhibition in a mouse model of inflammatory joint disease, and to determine whether urinary sepiapterin levels, as measured in mice and healthy human volunteers, could be useful as a noninvasive, translational biomarker of SPR inhibition/target engagement. METHODS: The collagen antibody-induced arthritis (CAIA) model was used to induce joint inflammation in mice. The effects of pharmacologic inhibition of SPR on thresholds of heat-, cold-, and mechanical-evoked pain sensitivity and on signs of inflammation were tested in mice with CAIA. In addition, mice and healthy human volunteers were treated with SPR inhibitors, and changes in urinary sepiapterin levels were analyzed by high-performance liquid chromatography. RESULTS: CAIA in mice was characterized by 2 phases: in the acute inflammation (early) phase, joint inflammation and heat-, mechanical-, and cold-induced pain hypersensitivity were present, while in the postinflammation (late) phase, no joint inflammation was observed but heat- and mechanical-induced hypersensitivity, but not cold hypersensitivity, were present. Inhibition of SPR in mice with CAIA significantly attenuated the heat-induced hyperalgesia in both phases, and the mechanical allodynia in the late phase. Signs of inflammation were unaffected by SPR inhibition. Urinary tetrahydrobiopterin levels, as a marker of inflammatory pain, were increased during inflammation in mice with CAIA (2-fold increase over controls; P < 0.05) and significantly reduced by SPR inhibition (P < 0.05 versus vehicle-treated mice). Increased urinary sepiapterin levels in the presence of SPR inhibition in both mice and healthy human volunteers were associated with high sensitivity (70-85%) and high specificity (82-88%) for the prediction of SPR inhibition/target engagement. CONCLUSION: SPR inhibition reduces the pain associated with joint inflammation, thus showing its potential utility as an analgesic strategy for inflammatory joint pain. In addition, SPR inhibition increases urinary sepiapterin levels, indicating the potential of this measurement as a noninvasive biomarker of target engagement of SPR inhibitors, such as sulfasalazine, a disease-modifying antirheumatic drug that is currently used as a first-line treatment for rheumatoid arthritis.
引用
- Fujita M, Scheffer DDL, Turnes BL, et al. Sepiapterin Reductase Inhibition Leading to Selective Reduction of Inflammatory Joint Pain in Mice and Increased Urinary Sepiapterin Levels in Humans and Mice. Arthritis Rheumatol. 2019. PMID: 31350812. doi:10.1002/art.41060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。